



# UC San Diego Parkinson's Support Group Network

*About Parkinson's · For Parkinson's · By Parkinson's*

---

December 28, 2021

Re: Proposal submitted by the *Research Group*:

Dr. Ruben Dagda  
University of Nevada Reno, School of Medicine  
Department of Pharmacology; MS 0318  
Reno NV, 89557

Raul Y. Dagda, Chief Scientific Officer  
CNS Curative Technologies LLC  
100 North Arlington Avenue, Suite 200  
Reno, NV 89501

To whom it may concern,

We are PhD scientists trained in molecular biology who have led the UC San Diego Parkinson's Support Group Network since 2012. David Higgins, himself, has Parkinson's Disease and David Miles is his care partner. Therefore, our connection to and interest in development of therapies for Parkinson's is personal.

We are excited to lend our enthusiastic support of this application from the Research Group led by Dr. Ruben Dagda and Raul Dagda for their out-of-the-box approach to treating Parkinson's. Levodopa, while a very successful treatment for Parkinson's, has been the primary therapy for 60 years. That's right, sixty years! The project proposed here addresses the inherent weaknesses of that therapy. Both the delivery method and the active pharmaceutical ingredient in the proposal are novel for Parkinson's therapy.

In keeping with the granting agency's vision to include patient perspectives on new drug development, this Research Group asked for access to our database of over 400 support group members. Our group members were impressed by the potential of the proposed novel technology. Furthermore, we were excited about the researcher's commitment to develop a therapeutic product that addresses the practical needs of people living with this disease. An example of patient-centered product development is their proposed use of intranasal delivery of the therapeutic agent. This type of delivery bypasses the gastrointestinal issues that interfere with nearly all Parkinson's therapies that depend on oral delivery.

The Research Group's commitment to incorporating patient perspectives was demonstrated to us when they interviewed over one hundred members of our group. This is the type of patient-centered product development that brings hope to the Parkinson's community for a better life.

We are all interested in a new, effective Parkinson's therapy. Based on the Research Group's experience and data generated to-date, we have no doubt that they will be in a position to address the critical questions to determine whether these compounds are effective in treating Parkinson's Disease. Funding this proposal will allow these researchers to take their work to the next level to explore the possibility of developing a game-changing Parkinson's therapy.

As members of the Parkinson's community, we enthusiastically support funding of this Research Group's work as outlined in their application.

Respectfully,

David R. Higgins, PhD  
[drhiggins@support4pd.org](mailto:drhiggins@support4pd.org)  
619-565-0411

David J. Miles, PhD  
[miles@support4pd.org](mailto:miles@support4pd.org)  
619-804-2400

---

Visit our website: [www.support4pd.org](http://www.support4pd.org)